Allero Therapeutics develops non-invasive immunotherapies using its proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform to induce long-lasting antigen-specific immune tolerance. The company targets immune-mediated disorders, including autoimmune diseases and allergies, by addressing the underlying immune response that leads to these conditions.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune and allergic diseases often involve systemic immunosuppression, leading to broad side effects and incomplete disease control. These treatments do not address the underlying cause of the disease, which is the immune system's inappropriate response to self-antigens or harmless environmental substances. There is a need for therapies that can specifically target and modulate the immune response to restore tolerance without compromising overall immunity.
Solution
Allero Therapeutics is developing a novel, non-invasive immunotherapy platform, Specific OroMucosal ImmunoTherapy (SOMIT), designed to induce antigen-specific immune tolerance. The SOMIT platform delivers antigens via the oral mucosa to modulate the immune response at the source, promoting long-lasting tolerance to specific antigens. This approach aims to address the root cause of immune-mediated disorders, including autoimmune diseases, allergies, and anti-drug antibody (ADA) formation, by re-educating the immune system to recognize these antigens as harmless. The company is initially focused on developing treatments for celiac disease and food allergies, with plans to expand its pipeline through partnerships.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases, allergies, and those at risk of developing anti-drug antibodies, as well as pharmaceutical companies seeking innovative immunotherapy approaches for partnership and development.
Features
- SOMIT platform for targeted antigen delivery via the oral mucosa
- Antigen-specific tolerance induction to address the underlying cause of immune-mediated disorders
- Non-invasive administration for improved patient compliance
- Potential for long-lasting therapeutic effects
- Applicability to a range of immune-mediated diseases, including autoimmune disorders, allergies, and ADA